arrow
M

Masaki Kobayashi

Institute of Science Tokyo
H指数:26
被引数:2,130

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

C-Reactive Protein/Albumin Ratio (CAR)-Integrated IMDC Model Improves Risk Stratification in Metastatic Renal Cell Carcinoma

C反应蛋白/白蛋白比值(CAR)整合的IMDC模型改善了转移性肾细胞癌的风险分层

Cancers
IF4.4
2026-04-290
OAAI
Ibuprofen gargle for quality of life and pain improvement in oral lichen planus: randomized crossover and long-term extension phase II study

布洛芬漱口液对口腔扁平苔藓患者生活质量和疼痛改善的随机交叉和长期扩展期II期研究

2026-01-080
PRE
Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial

阿帕卢他胺在亚洲转移性去势敏感前列腺癌患者中的临床疗效:TITAN试验的贝叶斯再分析

2025-12-010
PRE
Clinical Spectrum, Pathology, and Mechanisms of Anti-LGI4 Antibody-Positive Autoimmune Nodopathy
2025-11-010
PRE
Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios With Major Complications After Surgery for Renal Cell Carcinoma: A Pathway to Optimize Charlson Comorbidity Index and Preoperative Predictive Modeling

升高的中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值以及De Ritis比值与肾细胞癌术后主要并发症的关联:优化Charlson合并症指数和术前预测模型的一条途径

2025-11-011
PRE
Comparisons of Pembrolizumab Plus Lenvatinib, Nivolumab Plus Cabozantinib, and Cabozantinib Monotherapy in Advanced Non-Clear Cell Renal Cell Carcinoma Based on Individual Patient Data Reconstruction

基于个体患者数据重建的帕博利珠单抗联合仑伐替尼、纳武利尤单抗联合卡博替尼及卡博替尼单药治疗晚期非透明细胞肾细胞癌的比较

2025-11-010
PRE
Proposed tripartite classification of T1 renal cell carcinoma: Comparison with current binary system

T1肾细胞癌的三元分类法提案:与当前二元系统的比较

2025-11-010
PRE
DIFFERENTIAL IMPACT OF POSITIVE SURGICAL MARGIN IN HIGH-RISK LOCALIZED RENAL CELL CARCINOMA AFTER ADJUVANT AND NEOADJUVANT SYSTEMIC THERAPY: A MULTICENTER ANALYSIS
2024-05-010
PRE
A PROPENSITY SCORE-MATCHED ANALYSIS OF OUTCOMES OF NEOADJUVANT AND ADJUVANT SYSTEMIC THERAPY IN HIGH-RISK LOCALIZED RENAL CELL CARCINOMA: IMPACT OF TIMING OF THERAPY AND POSITIVE MARGIN
2024-05-010
PRE